You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameNalbuphine
Accession NumberDB00844  (APRD01132)
TypeSmall Molecule
GroupsApproved
DescriptionA narcotic used as a pain medication. It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors. Nalbuphine is the only opioid analgesic that is not a controlled substance in the United States.
Structure
Thumb
Synonyms
N-Cyclobutylmethyl-4,5alpha-epoxy-3,6alpha,14-morphinantriol
Nalbufina
Nalbuphin
Nalbuphine
Nalbuphinum
External Identifiers
  • EN-2234 A
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Nubain Injection 10mg/mlsolution10 mgintramuscular; intravenous; subcutaneousSandoz Canada Incorporated1993-12-31Not applicableCanada
Nubain Injection 20mg/mlsolution20 mgintramuscular; intravenous; subcutaneousSandoz Canada Incorporated1993-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Nalbuphine Hydrochlorideinjection, solution20 mg/mLintramuscular; intravenous; subcutaneousMc Kesson Packaging Services Business Unit Of Mc Kesson Corporation2010-05-03Not applicableUs
Nalbuphine Hydrochlorideinjection, solution10 mg/mLintramuscular; intravenous; subcutaneousHospira, Inc.1989-02-03Not applicableUs
Nalbuphine Hydrochlorideinjection, solution10 mg/mLintramuscular; intravenous; subcutaneousGeneral Injectables & Vaccines, Inc2010-03-01Not applicableUs
Nalbuphine Hydrochlorideinjection, solution10 mg/mLintramuscular; intravenous; subcutaneousHospira, Inc.1989-02-03Not applicableUs
Nalbuphine Hydrochlorideinjection, solution10 mg/mLintramuscular; intravenous; subcutaneousCardinal Health1989-02-03Not applicableUs
Nalbuphine Hydrochlorideinjection, solution20 mg/mLintramuscular; intravenous; subcutaneousHospira, Inc.1989-02-03Not applicableUs
Nalbuphine Hydrochlorideinjection, solution10 mg/mLintramuscular; intravenous; subcutaneousCardinal Health1989-02-03Not applicableUs
Nalbuphine Hydrochlorideinjection, solution20 mg/mLintramuscular; intravenous; subcutaneousHospira, Inc.1989-02-03Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
MexifenMedicus
NalbuphineMylan
NalpainOrpha-Devel
NubainSandoz
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Nalbuphine hydrochloride
23277-43-2
Thumb
  • InChI Key: YZLZPSJXMWGIFH-BCXQGASESA-N
  • Monoisotopic Mass: 393.170686096
  • Average Mass: 393.904
DBSALT000125
Categories
UNIIL2T84IQI2K
CAS number20594-83-6
WeightAverage: 357.4434
Monoisotopic: 357.194008357
Chemical FormulaC21H27NO4
InChI KeyInChIKey=NETZHAKZCGBWSS-CEDHKZHLSA-N
InChI
InChI=1S/C21H27NO4/c23-14-5-4-13-10-16-21(25)7-6-15(24)19-20(21,17(13)18(14)26-19)8-9-22(16)11-12-2-1-3-12/h4-5,12,15-16,19,23-25H,1-3,6-11H2/t15-,16+,19-,20-,21+/m0/s1
IUPAC Name
(1S,5R,13R,14S,17S)-4-(cyclobutylmethyl)-12-oxa-4-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7,9,11(18)-triene-10,14,17-triol
SMILES
O[[email protected]]1CC[C@@]2(O)[[email protected]]3CC4=CC=C(O)C5=C4[C@@]2(CCN3CC2CCC2)[[email protected]]1O5
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as morphinans. These are polycyclic compounds with a four-ring skeleton with three condensed six-member rings forming a partially hydrogenated phenanthrene moiety, one of which is aromatic while the two others are alicyclic.
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
ClassMorphinans
Sub ClassNot Available
Direct ParentMorphinans
Alternative Parents
Substituents
  • Morphinan
  • Benzylisoquinoline
  • Phenanthrene
  • Tetralin
  • Benzofuran
  • Aralkylamine
  • Alkyl aryl ether
  • Benzenoid
  • Piperidine
  • Tertiary alcohol
  • Cyclic alcohol
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary alcohol
  • Polyol
  • 1,2-aminoalcohol
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the relief of moderate to severe pain.
PharmacodynamicsNalbuphine is a synthetic opioid agonist-antagonist analgesic of the phenanthrene series. Nalbuphine's analgesic potency is essentially equivalent to that of morphine on a milligram basis. The opioid antagonist activity of nalbuphine is one-fourth as potent as nalorphine and 10 times that of pentazocine. Nalbuphine by itself has potent opioid antagonist activity at doses equal to or lower than its analgesic dose. When administered following or concurrent with mu agonist opioid analgesics (e.g., morphine, oxymorphone, fentanyl), nalbuphine may partially reverse or block opioid-induced respiratory depression from the mu agonist analgesic. Nalbuphine may precipitate withdrawal in patients dependent on opioid drugs. Nalbuphine should be used with caution in patients who have been receiving mu opioid analgesics on a regular basis.
Mechanism of actionThe exact mechanism of action is unknown, but is believed to interact with an opiate receptor site in the CNS (probably in or associated with the limbic system). The opiate antagonistic effect may result from competitive inhibition at the opiate receptor, but may also be a result of other mechanisms. Nalbuphine is thought primarily to be a kappa agonist. It is also a partial mu antagonist analgesic, with some binding to the delta receptor and minimal agonist activity at the sigma receptor.
Related Articles
AbsorptionThe mean absolute bioavailability was 81% and 83% for the 10 and 20 mg intramuscular doses, respectively, and 79% and 76% following 10 and 20 mg of subcutaneous nalbuphine.
Volume of distributionNot Available
Protein bindingNot appreciably bound.
MetabolismNot Available
Route of eliminationNot Available
Half lifeThe plasma half-life of nalbuphine is 5 hours, and in clinical studies the duration of analgesic activity has been reported to range from 3 to 6 hours.
ClearanceNot Available
ToxicityOral, acute LD50 is 1100 mg/kg in dog. Symptoms of overdose include primarily sleepiness and mild dysphoria.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Nalbuphine Action PathwayDrug actionSMP00691
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.968
Blood Brain Barrier+0.9642
Caco-2 permeable+0.7337
P-glycoprotein substrateSubstrate0.8532
P-glycoprotein inhibitor INon-inhibitor0.8781
P-glycoprotein inhibitor IINon-inhibitor0.8923
Renal organic cation transporterInhibitor0.5431
CYP450 2C9 substrateNon-substrate0.8645
CYP450 2D6 substrateSubstrate0.5896
CYP450 3A4 substrateSubstrate0.5919
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9421
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9029
CYP450 3A4 inhibitorNon-inhibitor0.93
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9562
Ames testNon AMES toxic0.6897
CarcinogenicityNon-carcinogens0.9598
BiodegradationNot ready biodegradable0.9796
Rat acute toxicity2.6502 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.747
hERG inhibition (predictor II)Non-inhibitor0.8054
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Injection, solutionintramuscular; intravenous; subcutaneous10 mg/mL
Injection, solutionintramuscular; intravenous; subcutaneous20 mg/mL
Solutionintramuscular; intravenous; subcutaneous10 mg
Solutionintramuscular; intravenous; subcutaneous20 mg
Prices
Unit descriptionCostUnit
Nubain 20 mg/ml ampule4.9USD ml
Nubain 10 mg/ml vial3.53USD ml
Nalbuphine 20 mg/ml ampul3.2USD ml
Nalbuphine 200 mg/10 ml vial2.66USD ml
Nalbuphine 10 mg/ml ampul1.46USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point230 °C as HCl saltNot Available
water solubility35.5 mg/mL at 25 °C as HCl saltNot Available
logP1.4Not Available
pKa8.71 and 9.96 (hcl form)FDA Label
Predicted Properties
PropertyValueSource
Water Solubility2.09 mg/mLALOGPS
logP2ALOGPS
logP1.19ChemAxon
logS-2.2ALOGPS
pKa (Strongest Acidic)7.45ChemAxon
pKa (Strongest Basic)13.75ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area73.16 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity97 m3·mol-1ChemAxon
Polarizability38.59 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Michael R. Magruder, “Nalbuphine-narcotic analgesic composition and method of producing analgesia.” U.S. Patent US4366159, issued August, 1981.

US4366159
General References
  1. Gear RW, Miaskowski C, Gordon NC, Paul SM, Heller PH, Levine JD: The kappa opioid nalbuphine produces gender- and dose-dependent analgesia and antianalgesia in patients with postoperative pain. Pain. 1999 Nov;83(2):339-45. [PubMed:10534607 ]
External Links
ATC CodesN02AF02
AHFS Codes
  • 28:08.12
PDB EntriesNot Available
FDA labelDownload (51.4 KB)
MSDSDownload (74.4 KB)
Interactions
Drug Interactions
Drug
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Nalbuphine.
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may increase the analgesic activities of Nalbuphine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Nalbuphine is combined with 7-Nitroindazole.
AcepromazineAcepromazine may increase the hypotensive activities of Nalbuphine.
AcepromazineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Aceprometazine.
AcetazolamideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Acetazolamide.
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Nalbuphine.
adipiplonThe risk or severity of adverse effects can be increased when Nalbuphine is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Alfaxalone.
AlfentanilNalbuphine may decrease the analgesic activities of Alfentanil.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Nalbuphine.
AlimemazineAlimemazine may increase the hypotensive activities of Nalbuphine.
AlphacetylmethadolNalbuphine may decrease the analgesic activities of Alphacetylmethadol.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Nalbuphine.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Nalbuphine.
AlvimopanThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Alvimopan.
AmilorideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Amiloride.
AmisulprideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Amitriptyline.
Ammonium chlorideAmmonium chloride may increase the excretion rate of Nalbuphine which could result in a higher serum level.
AmobarbitalThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Amobarbital.
AmoxapineNalbuphine may increase the serotonergic activities of Amoxapine.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Nalbuphine.
AmperozideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Amperozide.
AmphetamineAmphetamine may increase the analgesic activities of Nalbuphine.
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Nalbuphine.
AripiprazoleThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Aripiprazole.
ArticaineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Asenapine.
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Nalbuphine.
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Nalbuphine.
AzaperoneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Azaperone.
AzelastineNalbuphine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Nalbuphine.
AzosemideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Azosemide.
BaclofenThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Barbital.
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Nalbuphine.
BendroflumethiazideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Bendroflumethiazide.
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Nalbuphine.
BenzocaineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Benzocaine.
BenzphetamineBenzphetamine may increase the analgesic activities of Nalbuphine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Benzyl alcohol.
BezitramideNalbuphine may decrease the analgesic activities of Bezitramide.
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Nalbuphine.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Nalbuphine.
BrimonidineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Bromazepam.
BrompheniramineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Brotizolam.
BumetanideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Bumetanide.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Nalbuphine.
BuprenorphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Buprenorphine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Nalbuphine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Nalbuphine.
ButacaineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Nalbuphine.
Canrenoic acidThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Canrenoic acid.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Nalbuphine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Carbinoxamine.
CarfentanilNalbuphine may decrease the analgesic activities of Carfentanil.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Nalbuphine.
CarisoprodolThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Carisoprodol.
CetirizineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Nalbuphine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Chloroprocaine.
ChlorothiazideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Chlorothiazide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Chlorphenamine.
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Nalbuphine.
ChlorphentermineChlorphentermine may increase the analgesic activities of Nalbuphine.
ChlorpromazineChlorpromazine may increase the hypotensive activities of Nalbuphine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Chlorprothixene.
ChlorthalidoneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Chlorthalidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Chlorzoxazone.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Nalbuphine.
CitalopramNalbuphine may increase the serotonergic activities of Citalopram.
ClemastineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Nalbuphine is combined with clomethiazole.
ClomipramineNalbuphine may increase the serotonergic activities of Clomipramine.
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Nalbuphine.
ClonazepamThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Nalbuphine.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Nalbuphine.
CocaineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Cocaine.
CodeineNalbuphine may decrease the analgesic activities of Codeine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Nalbuphine.
ConivaptanThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Conivaptan.
CyclizineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Cyclobenzaprine.
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Nalbuphine.
CyclothiazideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Cyclothiazide.
CyproheptadineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Cyproheptadine.
DantroleneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Nalbuphine.
DapoxetineNalbuphine may increase the serotonergic activities of Dapoxetine.
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Nalbuphine.
deramciclaneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Desflurane.
DesipramineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Nalbuphine.
DesmopressinThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Desmopressin.
DetomidineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Detomidine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Dexbrompheniramine.
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Nalbuphine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Nalbuphine.
DextroamphetamineDextroamphetamine may increase the analgesic activities of Nalbuphine.
DextromoramideNalbuphine may decrease the analgesic activities of Dextromoramide.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Nalbuphine.
DextropropoxypheneNalbuphine may decrease the analgesic activities of Dextropropoxyphene.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Nalbuphine.
DezocineNalbuphine may decrease the analgesic activities of Dezocine.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Nalbuphine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Nalbuphine.
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Nalbuphine.
DifenoxinThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Difenoxin.
DihydrocodeineNalbuphine may decrease the analgesic activities of Dihydrocodeine.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Nalbuphine.
DihydroetorphineNalbuphine may decrease the analgesic activities of Dihydroetorphine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Nalbuphine.
DihydromorphineNalbuphine may decrease the analgesic activities of Dihydromorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Nalbuphine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Diphenhydramine.
DiphenoxylateNalbuphine may decrease the analgesic activities of Diphenoxylate.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Nalbuphine.
DoramectinThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Doxepin.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Nalbuphine.
DoxylamineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Doxylamine.
DPDPENalbuphine may decrease the analgesic activities of DPDPE.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Nalbuphine.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Nalbuphine.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Nalbuphine.
DrospirenoneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Drospirenone.
DrotebanolThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Drotebanol.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Nalbuphine.
EcgonineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Nalbuphine is combined with ECGONINE METHYL ESTER.
EfavirenzThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Efavirenz.
EfonidipineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Efonidipine.
EluxadolineNalbuphine may increase the constipating activities of Eluxadoline.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Nalbuphine.
EntacaponeThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Entacapone.
EplerenoneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Eplerenone.
EscitalopramNalbuphine may increase the serotonergic activities of Escitalopram.
EstazolamThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Estazolam.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Nalbuphine.
Etacrynic acidThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Etacrynic acid.
EthanolNalbuphine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Nalbuphine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Nalbuphine.
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Nalbuphine.
EthosuximideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ethotoin.
EthoxzolamideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ethoxzolamide.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ethyl loflazepate.
EthylmorphineNalbuphine may decrease the analgesic activities of Ethylmorphine.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Nalbuphine.
EtidocaineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Nalbuphine.
EtoperidoneNalbuphine may increase the serotonergic activities of Etoperidone.
EtorphineNalbuphine may decrease the analgesic activities of Etorphine.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Nalbuphine.
EzogabineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Fencamfamine.
FenfluramineNalbuphine may increase the serotonergic activities of Fenfluramine.
FentanylNalbuphine may decrease the analgesic activities of Fentanyl.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Nalbuphine.
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Nalbuphine.
FexofenadineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Flunitrazepam.
FluoxetineNalbuphine may increase the serotonergic activities of Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Flupentixol.
FluphenazineFluphenazine may increase the hypotensive activities of Nalbuphine.
FluphenazineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Fluphenazine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Nalbuphine.
FluspirileneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Fluticasone Propionate.
FluvoxamineNalbuphine may increase the serotonergic activities of Fluvoxamine.
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Nalbuphine.
FosphenytoinThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Fospropofol.
FurosemideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Furosemide.
GabapentinThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Nalbuphine is combined with gabapentin enacarbil.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Nalbuphine.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Gamma Hydroxybutyric Acid.
GlutethimideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Glutethimide.
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Nalbuphine.
GuanfacineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Nalbuphine.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Nalbuphine.
HalothaneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Halothane.
HeroinNalbuphine may decrease the analgesic activities of Heroin.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Nalbuphine.
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Nalbuphine.
HexobarbitalThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Hexobarbital.
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Nalbuphine.
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Hydrochlorothiazide.
HydrocodoneNalbuphine may decrease the analgesic activities of Hydrocodone.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Nalbuphine.
HydroflumethiazideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Hydroflumethiazide.
HydromorphoneNalbuphine may decrease the analgesic activities of Hydromorphone.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Nalbuphine.
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may increase the analgesic activities of Nalbuphine.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Nalbuphine.
HydroxyzineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Hydroxyzine.
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Nalbuphine.
IloperidoneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Iloperidone.
ImipramineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Imipramine.
IndalpineNalbuphine may increase the serotonergic activities of Indalpine.
IndapamideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Indapamide.
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Nalbuphine.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Nalbuphine.
IsosorbideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Isosorbide.
KetamineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ketazolam.
KetobemidoneNalbuphine may decrease the analgesic activities of Ketobemidone.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Nalbuphine.
KW-3902The risk or severity of adverse effects can be increased when Nalbuphine is combined with KW-3902.
LamotrigineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Levodopa.
Levomethadyl AcetateNalbuphine may decrease the analgesic activities of Levomethadyl Acetate.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Nalbuphine.
LevomilnacipranNalbuphine may increase the serotonergic activities of Levomilnacipran.
LevorphanolNalbuphine may decrease the analgesic activities of Levorphanol.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Nalbuphine.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Nalbuphine.
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Nalbuphine.
LithiumThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Lithium.
LofentanilNalbuphine may decrease the analgesic activities of Lofentanil.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Nalbuphine.
LoratadineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Nalbuphine.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Nalbuphine.
Lu AA21004Nalbuphine may increase the serotonergic activities of Lu AA21004.
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Nalbuphine.
LurasidoneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Nalbuphine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Magnesium Sulfate.
MannitolThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Mannitol.
MaprotilineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Maprotiline.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Nalbuphine.
MeclizineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Melperone.
MephentermineMephentermine may increase the analgesic activities of Nalbuphine.
MepivacaineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Mepivacaine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Nalbuphine.
MersalylThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Mersalyl.
MesoridazineMesoridazine may increase the hypotensive activities of Nalbuphine.
MesoridazineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Metaxalone.
MethadoneNalbuphine may decrease the analgesic activities of Methadone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Nalbuphine.
Methadyl AcetateNalbuphine may decrease the analgesic activities of Methadyl Acetate.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Nalbuphine.
MethamphetamineMethamphetamine may increase the analgesic activities of Nalbuphine.
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Nalbuphine.
MethapyrileneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Methaqualone.
MethazolamideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Methazolamide.
MethocarbamolThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Nalbuphine.
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Nalbuphine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Methsuximide.
MethyclothiazideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Methyclothiazide.
Methylene blueMethylene blue may increase the hypotensive activities of Nalbuphine.
MethylnaltrexoneThe risk or severity of adverse effects can be increased when Methylnaltrexone is combined with Nalbuphine.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Methylphenobarbital.
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Nalbuphine.
MetolazoneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Metolazone.
MetyrosineNalbuphine may increase the sedative activities of Metyrosine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Nalbuphine.
MilnacipranNalbuphine may increase the serotonergic activities of Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Nalbuphine.
MirtazapineNalbuphine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Nalbuphine.
MolindoneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Molindone.
MoricizineMoricizine may increase the hypotensive activities of Nalbuphine.
MorphineNalbuphine may decrease the analgesic activities of Morphine.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Nalbuphine.
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when N-butylscopolammonium bromide is combined with Nalbuphine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Nalbuphine.
NabiloneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Nabilone.
NaloxegolThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Naloxegol.
NaltrexoneThe therapeutic efficacy of Nalbuphine can be decreased when used in combination with Naltrexone.
NitrazepamThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Nitrous oxide.
NormethadoneNalbuphine may decrease the analgesic activities of Normethadone.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Nalbuphine.
NortriptylineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Nortriptyline.
NVA237The risk or severity of adverse effects can be increased when NVA237 is combined with Nalbuphine.
OlanzapineNalbuphine may increase the serotonergic activities of Olanzapine.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Nalbuphine.
OlopatadineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ondansetron.
OpiumNalbuphine may decrease the analgesic activities of Opium.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Nalbuphine.
OrphenadrineNalbuphine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Nalbuphine.
OsanetantThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Osanetant.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Nalbuphine.
OxprenololThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Oxybuprocaine.
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Nalbuphine.
OxycodoneNalbuphine may decrease the analgesic activities of Oxycodone.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Nalbuphine.
OxymorphoneNalbuphine may decrease the analgesic activities of Oxymorphone.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Nalbuphine.
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Nalbuphine.
PaliperidoneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Paliperidone.
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Nalbuphine.
ParaldehydeNalbuphine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Nalbuphine.
ParoxetineNalbuphine may increase the serotonergic activities of Paroxetine.
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Nalbuphine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Nalbuphine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Nalbuphine.
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Nalbuphine.
PerampanelThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Perospirone.
PerphenazinePerphenazine may increase the hypotensive activities of Nalbuphine.
PerphenazineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Perphenazine.
PethidineNalbuphine may decrease the analgesic activities of Pethidine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Nalbuphine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Phenoxyethanol.
PhenterminePhentermine may increase the analgesic activities of Nalbuphine.
PhenytoinThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Pimozide.
PipamperoneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Pipamperone.
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Nalbuphine.
PipotiazineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Pipotiazine.
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Nalbuphine.
PiretanideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Piretanide.
PizotifenThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Pizotifen.
PolythiazideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Polythiazide.
PomalidomideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Pomalidomide.
PotassiumThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Potassium.
Potassium CitrateThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Potassium Citrate.
PramipexoleNalbuphine may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Nalbuphine.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Nalbuphine.
PrimidoneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Nalbuphine.
ProchlorperazineProchlorperazine may increase the hypotensive activities of Nalbuphine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Prochlorperazine.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Nalbuphine.
PromazinePromazine may increase the hypotensive activities of Nalbuphine.
PromazineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Promazine.
PromethazinePromethazine may increase the hypotensive activities of Nalbuphine.
PromethazineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Promethazine.
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Nalbuphine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Nalbuphine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Nalbuphine.
PropoxycaineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Nalbuphine is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Quetiapine.
QuinethazoneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Quinethazone.
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Nalbuphine.
RamelteonThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ramelteon.
RamosetronNalbuphine may increase the constipating activities of Ramosetron.
RemifentanilNalbuphine may decrease the analgesic activities of Remifentanil.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Nalbuphine.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Nalbuphine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Nalbuphine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Nalbuphine.
RomifidineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Romifidine.
RopiniroleNalbuphine may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Nalbuphine.
RotigotineNalbuphine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Nalbuphine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Nalbuphine is combined with S-Ethylisothiourea.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Nalbuphine.
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Nalbuphine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Nalbuphine.
SertindoleThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Sertindole.
SertralineNalbuphine may increase the serotonergic activities of Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Sevoflurane.
Sodium oxybateThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Sodium oxybate.
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Nalbuphine.
SpironolactoneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Spironolactone.
StiripentolThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Stiripentol.
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Nalbuphine.
SufentanilNalbuphine may decrease the analgesic activities of Sufentanil.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Nalbuphine.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Nalbuphine.
SuvorexantThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Suvorexant.
TapentadolNalbuphine may decrease the analgesic activities of Tapentadol.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Nalbuphine.
TasimelteonThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Tasimelteon.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Nalbuphine.
TetrabenazineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Tetrodotoxin.
ThalidomideNalbuphine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Nalbuphine.
TheobromineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Theobromine.
ThiamylalThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Thiamylal.
ThiethylperazineThiethylperazine may increase the hypotensive activities of Nalbuphine.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Nalbuphine.
ThioridazineThioridazine may increase the hypotensive activities of Nalbuphine.
ThioridazineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Thioridazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Tiagabine.
TicrynafenThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ticrynafen.
TiletamineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Tiletamine.
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Nalbuphine.
TizanidineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Tizanidine.
TolcaponeThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Tolcapone.
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Nalbuphine.
TolvaptanThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Tolvaptan.
TopiramateThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Topiramate.
TorasemideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Torasemide.
TramadolNalbuphine may decrease the analgesic activities of Tramadol.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Nalbuphine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Nalbuphine.
TrazodoneNalbuphine may increase the serotonergic activities of Trazodone.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Nalbuphine.
TriamtereneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Triamterene.
TriazolamThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Triazolam.
TrichlormethiazideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Trichlormethiazide.
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Nalbuphine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Trifluoperazine.
TriflupromazineTriflupromazine may increase the hypotensive activities of Nalbuphine.
TriflupromazineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Triflupromazine.
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Nalbuphine.
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Nalbuphine.
TrimipramineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Triprolidine.
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Nalbuphine.
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Nalbuphine.
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Nalbuphine.
UlaritideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ularitide.
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Nalbuphine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Nalbuphine.
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Nalbuphine.
VigabatrinThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Vigabatrin.
VilazodoneNalbuphine may increase the serotonergic activities of Vilazodone.
VortioxetineNalbuphine may increase the serotonergic activities of Vortioxetine.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Nalbuphine.
XylazineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ziconotide.
ZimelidineNalbuphine may increase the serotonergic activities of Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Nalbuphine.
ZolazepamThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Nalbuphine.
ZonisamideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates th...
Gene Name:
OPRK1
Uniprot ID:
P41145
Molecular Weight:
42644.665 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Hoehe M, Duka T: Opiates increase plasma catecholamines in humans. Psychoneuroendocrinology. 1993;18(2):141-8. [PubMed:8388112 ]
  4. Chen SL, Huang EY, Chow LH, Tao PL: Dextromethorphan differentially affects opioid antinociception in rats. Br J Pharmacol. 2005 Feb;144(3):400-4. [PubMed:15655510 ]
  5. Tao PL, Liang KW, Sung WY, Wu YT, Huang EY: Nalbuphine is effective in decreasing the rewarding effect induced by morphine in rats. Drug Alcohol Depend. 2006 Sep 15;84(2):175-81. Epub 2006 Mar 6. [PubMed:16517095 ]
  6. Smith MA, Greene-Naples JL, Lyle MA, Iordanou JC, Felder JN: The effects of repeated opioid administration on locomotor activity: I. Opposing actions of mu and kappa receptors. J Pharmacol Exp Ther. 2009 Aug;330(2):468-75. doi: 10.1124/jpet.108.150011. Epub 2009 Apr 29. [PubMed:19403853 ]
  7. Mello NK, Mendelson JH, Sholar MB, Jaszyna-Gasior M, Goletiani N, Siegel AJ: Effects of the mixed mu/kappa opioid nalbuphine on cocaine-induced changes in subjective and cardiovascular responses in men. Neuropsychopharmacology. 2005 Mar;30(3):618-32. [PubMed:15602503 ]
  8. Gear RW, Miaskowski C, Gordon NC, Paul SM, Heller PH, Levine JD: The kappa opioid nalbuphine produces gender- and dose-dependent analgesia and antianalgesia in patients with postoperative pain. Pain. 1999 Nov;83(2):339-45. [PubMed:10534607 ]
  9. Peng X, Knapp BI, Bidlack JM, Neumeyer JL: Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors. J Med Chem. 2007 May 3;50(9):2254-8. Epub 2007 Apr 4. [PubMed:17407276 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Voltage-gated calcium channel activity
Specific Function:
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociati...
Gene Name:
OPRM1
Uniprot ID:
P35372
Molecular Weight:
44778.855 Da
References
  1. Kishioka S, Ko MC, Woods JH: Diltiazem enhances the analgesic but not the respiratory depressant effects of morphine in rhesus monkeys. Eur J Pharmacol. 2000 May 26;397(1):85-92. [PubMed:10844102 ]
  2. Hoehe M, Duka T: Opiates increase plasma catecholamines in humans. Psychoneuroendocrinology. 1993;18(2):141-8. [PubMed:8388112 ]
  3. Zernig G, Lewis JW, Woods JH: Clocinnamox inhibits the intravenous self-administration of opioid agonists in rhesus monkeys: comparison with effects on opioid agonist-mediated antinociception. Psychopharmacology (Berl). 1997 Feb;129(3):233-42. [PubMed:9084061 ]
  4. Picker MJ: Discriminative stimulus effects of the mixed-opioid agonist/antagonist dezocine: cross-substitution by mu and delta opioid agonists. J Pharmacol Exp Ther. 1997 Dec;283(3):1009-17. [PubMed:9399970 ]
  5. McNicol ED, Boyce D, Schumann R, Carr DB: Mu-opioid antagonists for opioid-induced bowel dysfunction. Cochrane Database Syst Rev. 2008 Apr 16;(2):CD006332. doi: 10.1002/14651858.CD006332.pub2. [PubMed:18425947 ]
  6. Tao PL, Liang KW, Sung WY, Wu YT, Huang EY: Nalbuphine is effective in decreasing the rewarding effect induced by morphine in rats. Drug Alcohol Depend. 2006 Sep 15;84(2):175-81. Epub 2006 Mar 6. [PubMed:16517095 ]
  7. Smith MA, Greene-Naples JL, Lyle MA, Iordanou JC, Felder JN: The effects of repeated opioid administration on locomotor activity: I. Opposing actions of mu and kappa receptors. J Pharmacol Exp Ther. 2009 Aug;330(2):468-75. doi: 10.1124/jpet.108.150011. Epub 2009 Apr 29. [PubMed:19403853 ]
  8. Mello NK, Mendelson JH, Sholar MB, Jaszyna-Gasior M, Goletiani N, Siegel AJ: Effects of the mixed mu/kappa opioid nalbuphine on cocaine-induced changes in subjective and cardiovascular responses in men. Neuropsychopharmacology. 2005 Mar;30(3):618-32. [PubMed:15602503 ]
  9. Meerpohl JJ, Timmer A: [News from the cochrane library: mu opioid antagonists for opioid-induced bowel dysfunction]. Z Gastroenterol. 2008 Sep;46(9):917-21. doi: 10.1055/s-2008-1027720. Epub 2008 Sep 22. [PubMed:18810678 ]
  10. Peng X, Knapp BI, Bidlack JM, Neumeyer JL: Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors. J Med Chem. 2007 May 3;50(9):2254-8. Epub 2007 Apr 4. [PubMed:17407276 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurot...
Gene Name:
OPRD1
Uniprot ID:
P41143
Molecular Weight:
40368.235 Da
References
  1. Chen JC, Smith ER, Cahill M, Cohen R, Fishman JB: The opioid receptor binding of dezocine, morphine, fentanyl, butorphanol and nalbuphine. Life Sci. 1993;52(4):389-96. [PubMed:8093631 ]
  2. De Souza EB, Schmidt WK, Kuhar MJ: Nalbuphine: an autoradiographic opioid receptor binding profile in the central nervous system of an agonist/antagonist analgesic. J Pharmacol Exp Ther. 1988 Jan;244(1):391-402. [PubMed:2826773 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23